See more : BuzzFeed, Inc. (BZFD) Income Statement Analysis – Financial Results
Complete financial analysis of Evogene Ltd. (EVGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evogene Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Blue Moon Metals Inc. (BMOOF) Income Statement Analysis – Financial Results
- Heubach Colorants India Limited (HEUBACHIND.BO) Income Statement Analysis – Financial Results
- Cohen & Company Inc. (COHN) Income Statement Analysis – Financial Results
- MGX Minerals Inc. (XMG.CN) Income Statement Analysis – Financial Results
- Rayong Wire Industries Public Company Limited (RWI.BK) Income Statement Analysis – Financial Results
Evogene Ltd. (EVGN)
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.64M | 1.68M | 930.00K | 1.04M | 753.00K | 1.75M | 3.38M | 6.54M | 11.13M | 14.51M | 17.58M | 17.07M | 14.90M |
| Cost of Revenue | 4.24M | 909.00K | 767.00K | 574.00K | 334.00K | 1.45M | 2.85M | 5.64M | 8.26M | 9.71M | 10.11M | 9.55M | 8.25M |
| Gross Profit | 1.40M | 766.00K | 163.00K | 466.00K | 419.00K | 295.00K | 536.00K | 901.00K | 2.87M | 4.80M | 7.47M | 7.52M | 6.65M |
| Gross Profit Ratio | 24.80% | 45.73% | 17.53% | 44.81% | 55.64% | 16.89% | 15.85% | 13.78% | 25.82% | 33.09% | 42.47% | 44.05% | 44.65% |
| Research & Development | 18.11M | 20.79M | 23.86M | 19.96M | 17.82M | 16.77M | 18.67M | 18.10M | 16.41M | 15.87M | 12.62M | 7.25M | 6.38M |
| General & Administrative | 8.67M | 6.48M | 7.25M | 5.32M | 3.77M | 3.51M | 3.81M | 3.89M | 4.38M | 4.19M | 3.56M | 3.39M | 3.45M |
| Selling & Marketing | 1.01M | 3.93M | 653.00K | 520.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.68M | 10.42M | 7.25M | 5.32M | 3.77M | 3.51M | 3.81M | 3.89M | 4.38M | 4.19M | 3.56M | 3.39M | 3.45M |
| Other Expenses | 0.00 | -3.50M | 0.00 | 15.02M | -41.00K | -120.00K | -67.00K | -33.00K | 0.00 | -231.00K | -147.00K | -205.00K | -156.00K |
| Operating Expenses | 27.79M | 27.71M | 31.12M | 25.28M | 21.59M | 20.28M | 22.48M | 21.99M | 20.80M | 20.06M | 16.19M | 10.65M | 9.84M |
| Cost & Expenses | 32.03M | 28.62M | 31.88M | 25.85M | 21.92M | 21.74M | 25.33M | 27.63M | 29.05M | 29.77M | 26.30M | 20.20M | 18.08M |
| Interest Income | 1.25M | 516.00K | 1.94M | 1.59M | 2.46M | 1.41M | 2.13M | 2.42M | 2.57M | 2.24M | 1.18M | 869.00K | 383.00K |
| Interest Expense | 171.00K | 3.33M | 1.41M | 2.95M | 386.00K | 2.21M | 1.01M | 891.00K | 1.86M | 1.52M | 1.34M | 89.00K | 7.00K |
| Depreciation & Amortization | 2.61M | 2.58M | 2.23M | 2.73M | 2.77M | 2.02M | 2.15M | 2.28M | 2.43M | 2.25M | 2.04M | 1.84M | 1.42M |
| EBITDA | -23.20M | -26.93M | -27.80M | -23.18M | -15.97M | -18.62M | -18.55M | -18.81M | -15.49M | -13.01M | -7.20M | -1.29M | -1.76M |
| EBITDA Ratio | -411.42% | -1,423.58% | -2,880.00% | -1,970.77% | -2,116.33% | -947.68% | -522.83% | -285.40% | -137.93% | -89.68% | -42.90% | -8.17% | -36.05% |
| Operating Income | -26.39M | -26.94M | -30.95M | -24.81M | -21.17M | -19.99M | -21.95M | -21.09M | -17.92M | -15.26M | -8.72M | -3.13M | -3.18M |
| Operating Income Ratio | -467.93% | -1,608.42% | -3,328.28% | -2,385.96% | -2,810.89% | -1,144.19% | -649.13% | -322.46% | -161.03% | -105.13% | -49.60% | -18.31% | -21.36% |
| Total Other Income/Expenses | 404.00K | 687.00K | 521.00K | -1.36M | 2.08M | -793.00K | -1.73M | 1.53M | 708.00K | 726.00K | -157.00K | 678.00K | 3.83M |
| Income Before Tax | -25.99M | -29.75M | -30.43M | -26.17M | -19.09M | -20.78M | -20.83M | -19.56M | -17.21M | -14.53M | -8.88M | -2.45M | 645.00K |
| Income Before Tax Ratio | -460.76% | -1,776.36% | -3,272.26% | -2,516.73% | -2,535.33% | -1,189.58% | -616.00% | -299.02% | -154.67% | -100.13% | -50.50% | -14.34% | 4.33% |
| Income Tax Expense | -33.00K | 90.00K | 13.00K | 32.00K | 24.00K | 30.00K | 11.00K | 36.00K | -2.20M | -1.80M | -1.67M | 74.00K | -3.83M |
| Net Income | -23.88M | -26.64M | -27.79M | -23.37M | -18.11M | -20.76M | -20.84M | -19.59M | -17.21M | -14.53M | -8.88M | -2.52M | 645.00K |
| Net Income Ratio | -423.39% | -1,590.33% | -2,988.49% | -2,247.50% | -2,405.31% | -1,188.21% | -616.33% | -299.57% | -154.67% | -100.13% | -50.50% | -14.77% | 4.33% |
| EPS | -5.23 | -6.46 | -6.87 | -8.30 | -0.70 | -0.81 | -0.81 | -0.77 | -0.68 | -0.58 | -0.45 | -0.14 | 0.04 |
| EPS Diluted | -5.23 | -6.46 | -6.87 | -8.30 | -0.70 | -0.81 | -0.81 | -0.77 | -0.68 | -0.58 | -0.45 | -0.14 | 0.03 |
| Weighted Avg Shares Out | 4.57M | 4.12M | 4.04M | 2.82M | 25.75M | 25.75M | 25.73M | 25.44M | 25.31M | 25.05M | 19.73M | 18.42M | 17.51M |
| Weighted Avg Shares Out (Dil) | 4.57M | 4.12M | 4.04M | 2.82M | 25.75M | 25.75M | 25.73M | 25.44M | 25.31M | 25.05M | 19.73M | 18.42M | 18.73M |
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
Evogene Reports Third Quarter 2024 Financial Results
EverGen Infrastructure Reports Q3 2024 Results
Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
EverGen Infrastructure Announces Dates for 2024 Third Quarter Financial Results and Conference Call
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
Evogene Schedules Third Quarter 2024 Financial Results Release
Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design
Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
Source: https://incomestatements.info
Category: Stock Reports